In our WGS-based cohort of 734 MDS patients we identified 231/734 (31%) cases with SF3B1 mutations verifying known hotspots in K700, K666 and H662 [4, 7, 8, 20, 21] and confirming a heterozygous SF3B1 mutation status with high median VAFs (35%) across all entities. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.